Trillion-Dollar Market—Investment Guide to the Golden Decade of Innovative Drugs (Chapter XI)

3. AbbVie: After Humira, the Autoimmune Empire Desperately Needs a New King AbbVie reported approximately $28 billion in total revenue for the first half of 2026, representing ~3% year-on-year growth. Due to biosimilar competition, Humira’s sales continued their decline to roughly $4 billion (half-year). The company’s full-year 2026 guidance projects revenue of $56–57 billion. To fill the massive gap in its autoimmune portfolio, AbbVie acquired Apogee for $10.9 billion, with the primary objective of securing Zumilokibart—a long-acting IL-17A monoclonal antibody. This acquisition logic closely aligns with InnoCare’s ICP-332 (an oral TYK2 inhibitor): the autoimmune field is shifting from injectables to oral therapeutics, and InnoCare stands at the global forefront of this wave. 4. Pfizer: A Billion-Dollar Bet on Oral Small-Molecule GLP-1 Pfizer reported approximately $31 billion in total revenue for the first half of 2026, representing ~6% year-on-year growth. Its full-year 2026 guidance projects revenue of $62–64 billion. Its lead candidate, Danuglipron, is undergoing regulatory submissions in multiple countries; upon approval, it will become the world’s second oral small-molecule GLP-1 receptor agonist—directly challenging Eli Lilly’s first-to-market Orforglipron. For upstream CDMO partner Asymchem, this represents enormous commercial order potential. 5. Eli Lilly: Tirzepatide Challenges for Global Drug King; Oral GLP-1 Poised for Takeoff Eli Lilly reported approximately $28 billion in total revenue for the first half of 2026, representing ~25% year-on-year growth. Of this, tirzepatide generated ~$13 billion globally—rapidly closing in on Keytruda. The company’s full-year 2026 guidance forecasts revenue of $57–59 billion, with tirzepatide expected to generate $27–29 billion annually. More critically, its oral small-molecule GLP-1 (Orforglipron) has entered the final stage of Phase III clinical trials and is anticipated to gain regulatory approval in 2027–2028, becoming the world’s first approved oral small-molecule GLP-1 therapy. During its earnings call, Lilly’s management explicitly stated that the GLP-1 market is “far from peaking,” and oral small molecules represent the next explosive growth frontier. 6. Sanofi: After Dupixent, Autoimmune Pipeline Still Needs Reinforcement Sanofi reported approximately €23 billion in total revenue for the first half of 2026, representing ~7% year-on-year growth. Dupixent generated ~€6.5 billion globally (half-year), remaining its core growth engine. The company’s full-year 2026 guidance forecasts mid-to-high single-digit percentage revenue growth. To prepare for Dupixent’s upcoming patent expiry, Sanofi is actively pursuing business development opportunities for next-generation autoimmune assets—particularly oral TYK2 inhibitors (e.g., InnoCare’s ICP-332) and long-acting IL-4Rα antibodies. These MNCs’ financial results and forward guidance—backed by hundreds of billions of dollars in real capital—validate the era-defining value of China’s innovative drug assets. From Merck’s ADC empire to Roche’s bispecific antibody bet, from Pfizer’s GLP-1 wager to AbbVie’s autoimmune acquisitions—every transaction and every earnings forecast rests upon one or more Chinese innovative biopharma companies riding the crest of the wave.

Sanofi’s 2025 Strategic Landscape: M&A, AI, and Policy Navigation Reshaping the Competitive Positioning of Pharma Companies

To deliver on this commitment, Sanofi pioneered the ‘Eco-Design’ philosophy on the R&D front. Starting in 2025, Sanofi mandates that all newly approved drugs and vaccines undergo carbon footprint assessment and optimization across their entire value chain—from raw material extraction and API synthesis, through formulation and packaging design, to end-of-life product disposal. On the operations front, the company has significantly increased its use of renewable electricity (targeting a jump from 11% in 2019 to 100% by 2030, in line with the RE100 initiative); in 2025, it achieved notable progress in energy consumption, reducing its market-based Scope 2 emissions by 67.9% versus the 2019 baseline (to 70 ktCO2e). Furthermore, Sanofi directly links executive compensation to ESG performance—climate and carbon metrics account for up to 10% of the annual variable compensation for its CEO and senior executives, embedding green strategy execution into the corporate governance architecture. 8. Deep Conclusions and Forward Outlook for 2026–2030 Through a deep-dive analysis spanning capital allocation, financial leverage, pipeline depth, cutting-edge technology reserves, macro-policy navigation, and competitive positioning vis-à-vis peers, we arrive at the following core conclusions regarding Sanofi’s current enterprise value and long-term evolution logic: First, Sanofi has successfully emerged from the ‘painful phase’ of strategic transformation and entered a high-quality dividend release period. The 2025 divestiture of Opella Consumer Healthcare—the boldest portfolio slimming action in a decade—completely severed the drag of low-margin, marketing-intensive businesses on Sanofi’s biopharma innovation core. This move positions Sanofi to advance unencumbered, backed by robust free cash flow exceeding €8 billion, squarely targeting peers like Novartis and Roche—high-margin ‘pure-play’ innovators. Second, the ‘Immune Supremacy’ strategy has built an exceptionally deep market moat. Dupixent’s extraordinary €15.7 billion in sales is not a peak—but rather the launchpad for expansion into broader Type 2 inflammation indications, including chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Crucially, rather than passively awaiting the core patent cliff looming in the early 2030s, Sanofi has proactively constructed an impenetrable, multi-tiered defense: a dense pipeline of late-stage follow-on assets (e.g., Amlitelimab, Frexalimab—each projected to achieve peak annual sales in the several-billion-euro range) and strategic acquisitions such as Blueprint Medicines’ rare-immunology portfolio. Third, the technological foundation has gained substantive anti-fragility. Sanofi keenly recognizes the inefficiency and high cost of traditional drug discovery—and has placed an all-in bet on AI systems across its entire value chain. Whether deploying its internally developed plai predictive and error-correction system trained on massive datasets, partnering externally with Exscientia and BioMap to accelerate target identification using multi-omics large language models and retrosynthetic robotics, or decisively terminating its seasonal flu mRNA vaccine program—lacking clear clinical differentiation—in favor of focusing on H5 pandemic and rare infectious disease vaccines, these moves collectively reflect an uncommon degree of scientific rigor and disciplined decision-making by Sanofi’s leadership.

Sanofi lifts expectations for 2026 sales growth, looks to M&A

10 hours ago

Sanofi raised its annual sales growth forecast to a low-teens percentage, driven by strong demand for Dupixent. The company also announced plans for potential M&A deals exceeding €5 billion to secure late-stage assets.

reuters

2026-09-30

Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal

2026-10-29

Sanofi lifts expectations for 2026 sales growth, looks to M&A

Sanofi lifts expectations for 2026 sales growth, looks to M&A

FAQ